1-2 of 2
Thérèse Aurran
Close
Sort by
Journal Articles

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

Clinical Trials & Observations
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini-Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran Schleinitz, Florence Cymbalista, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen-Khac, Pierre Feugier
Journal: Blood Advances
Blood Adv (2023) 7 (15): 3936–3945.
https://doi.org/10.1182/bloodadvances.2022009594
Published: 2023
Includes: Supplemental data
Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Clinical Trials & Observations
Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2438–2446.
https://doi.org/10.1182/bloodadvances.2020003895
Published: 2021
Includes: Supplemental data